Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Isabelle Gorin is active.

Publication


Featured researches published by Isabelle Gorin.


The Lancet | 1995

Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma

Nicolas Dupin; M. Grandadam; Vincent Calvez; Jean-Thierry Aubin; Jean-Marie Huraux; Henri Agut; Isabelle Gorin; S. Havard; F. Lamy; Michèle Leibowitch; Jean-Paul Escande

DNA sequences closely related to herpesvirus-like sequences have been found in AIDS-associated Kaposis sarcoma. Using PCR, we found herpesvirus-like DNA sequences in Kaposis lesions and normal adjacent skin in five patients with Mediterranean Kaposis sarcoma. We did not find these sequences in tissues from patients without Kaposis sarcoma. Semi-quantitative PCR revealed many more herpesvirus-like sequences in Kaposis lesions than in unaffected skin. Our results reinforce the hypothesis that an infectious agent closely related to gamma-herpesvirus is implicated in the pathogenesis of Mediterranean and AIDS-associated Kaposis sarcoma.


The Journal of Infectious Diseases | 1997

Exacerbations of Clinical Symptoms in Human Immunodeficiency Virus Type 1—Infected Patients with Multicentric Castleman's Disease Are Associated with a High Increase in Kaposi's Sarcoma Herpesvirus DNA Load in Peripheral Blood Mononuclear Cells

Marc Grandadam; Nicolas Dupin; Vincent Calvez; Isabelle Gorin; Laurent Blum; Serge Kernbaum; D. Sicard; Yves Buisson; Henri Agut; Jean Paul Escande; Jean Marie Huraux

The epidemiologic link between multicentric Castlemans disease (MCD) and Kaposis sarcoma (KS) and the high frequency of KS herpesvirus (KSHV) detection in both diseases raise the question of a role of this new virus in the pathogenesis of MCD. To explore this hypothesis, the KSHV DNA load was investigated in peripheral blood mononuclear cells of 3 human immunodeficiency virus (HIV)-infected patients with MCD at different points during the clinical course. Clinical parameters, such as fever and the presence of lymphadenopathy, were systematically assessed. Hemogram and C-reactive protein level determinations were performed as standard procedures. KSHV DNA load was investigated by means of semiquantitative polymerase chain reaction assay using peripheral blood mononuclear cells of the patients. A correlation between the variation in clinical and biologic parameters related to MCD and KSHV DNA load was found, suggesting a close relationship between KSHV and MCD in HIV-1-infected patients.


The Lancet | 1984

Plasma exchange in bullous pemphigoid.

Jean-Claude Roujeau; Patrice Morel; Eric Dalle; Bernard Guillot; Isabelle Gorin; Guy Lorette; Pierre Souteyrand; Jean-Claude Guillaume; B. Crickx; M.-S. Doutre; William Godard; Bruno Labeille; Gérard Rifle; Raoul Triller; J. Revuz

41 patients with pemphigoid entered a multicentre randomised study of the efficacy of plasma exchange. All patients received 0.3 mg/kg daily oral prednisolone, increased weekly if the disease remained active. 24 patients received plasma exchanges in addition (eight large-volume exchanges over 4 weeks), and 17 had prednisolone only. 4 patients, 2 in each group, were withdrawn from the study. The initial dose of prednisolone was effective in 13 of 22 patients receiving plasma exchange but in none of 15 patients receiving prednisolone only. Control of the disease was obtained with a mean daily prednisolone dose of 0.52 +/- 0.28 mg/kg in the plasma exchange group v 0.97 +/- 0.33 mg/kg in the other group and a mean cumulative dose of 1240 +/- 728 mg v 2770 +/- 1600 mg. This finding suggests that plasma exchange allows a substantial saving of corticosteroids in the management of pemphigoid. This sparing effect was observed whether or not serum anti-basement membrane antibodies had been detected before treatment.


British Journal of Cancer | 2006

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

V. Martinez; Eric Caumes; L. Gambotti; H. Ittah; Jean-Pierre Morini; Jean Deleuze; Isabelle Gorin; Christine Katlama; François Bricaire; Nicolas Dupin

Highly active antiretroviral therapy (HAART) reduces the incidence and improves the prognosis of Kaposis sarcoma (KS). This study was designed to identify factors associated with KS clinical responses in HIV-infected patients during HAART. We reviewed the files of 138 HIV-1-infected patients with KS. Epidemiologic and HIV-related clinical and biological parameters were recorded at KS diagnosis (baseline) and every 6 months thereafter. In a subset of 73 antiretroviral-naive patients, we compared the clinical outcome of KS according to the use or nonuse of protease inhibitors (PI). After 6 months of follow-up, KS remission was more frequent in patients who were naive of HAART and who were at ACTG stage S0 at baseline (P=0.03 and 0.02). Undetectable HIV viral load was strongly associated with KS remission (P⩽0.004 at all time points), while CD4 cell count was not. Among the 73 antiretroviral-naive patients at baseline, and who were studied for 24 months, KS outcome did not differ between patients who were prescribed PI-containing and PI-sparing regimens. Intercurrent multicentric Castlemans disease was associated with poor outcome after 60 months of follow-up (P⩽0.0001). Fourteen deaths occurred after a median follow-up of 37.5 months, eight of which were KS related. Suppression of HIV replication appears to be crucial to control KS. Non-PI-based regimens were equivalent to PI-based regimens as regards the clinical and virological outcome of antiretroviral-naive HIV-infected patients with KS.


British Journal of Dermatology | 1999

The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.

Nicolas Dupin; V. Rubin De Cervens; Isabelle Gorin; Vincent Calvez; E. Pessis; Marc Grandadam; C. Rabian; Jean-Paul Viard; Jean-Marie Huraux; Jean-Paul Escande

To assess the clinical and biological benefit of highly active antiretroviral therapy on AIDS‐associated Kaposis sarcoma (KS), 13 patients with AIDS‐associated Kaposis sarcoma (five pulmonary KS and eight cutaneous KS) were prospectively followed for a mean duration of 12 months. Six patients were treated with specific anti‐KS chemotherapy before or simultaneously with the introduction of antiretroviral therapy. Clinical response was assessed according to the AIDS Clinical Trial Group (ACTG) criteria. CD4 cell counts, plasma HIV‐1 RNA and human herpesvirus 8 (HHV‐8) viraemia were measured at baseline and at different points. Among patients with pulmonary KS, we observed three complete responses (CR), one partial response (PR) and one progression. The median survival time after the diagnosis of pulmonary KS was 15 months with a median duration of the response after the discontinuation of specific chemotherapy for KS of 8 months. Among patients with cutaneous KS, we observed four CR, three PR and one stable response. A complete response was significantly associated with a reversal in HHV‐8 viraemia (five of six vs. one of six; P = 0.02, Mann–Whitney test).


American Journal of Cardiology | 1988

Comparison Among Acquired Immune Deficiency Syndrome Patients With and Without Clinical Evidence of Cardiac Disease

Jean-Jacques Monsuez; Evlin L. Kinney; Daniel Vittecoq; Michel Kitzis; Willy Rozenbaum; Marie Françoise d'Agay; Michel Wolff; Claudie Marche; M. Janier; Isabelle Gorin; John M. Evans; Brigitte Autran

Abstract The expression of cardiac abnormalities in acquired immune deficiency syndrome (AIDS) has been interpreted in various ways, with some 1–11 reporting that heart disease in patients with AIDS is clinically silent, while others12-l7 have noted the opposite. We suspected that this apparent conflict in findings might be due in part to the difficulty in recognizing cardiac signs and symptoms in patients with AIDS. Recognition would be important if cardiac symptoms, in this population, are even a rough gauge of the severity of the cardiac abnormalities. This study characterizes the clinical features and effect on prognosis of cardiac abnormalities in AIDS.


British Journal of Cancer | 2006

PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study

Nadem Soufir; Bénédicte Gérard; Marc Portela; A Brice; M Liboutet; Philippe Saiag; Vincent Descamps; Delphine Kerob; P. Wolkenstein; Isabelle Gorin; Celeste Lebbe; Nicolas Dupin; B. Crickx; Nicole Basset-Seguin; Bernard Grandchamp

The patched (PTCH) mutation rate in nevoid basal cell carcinoma syndrome (NBCCS) reported in various studies ranges from 40 to 80%. However, few studies have investigated the role of PTCH in clinical conditions suggesting an inherited predisposition to basal cell carcinoma (BCC), although it has been suggested that PTCH polymorphisms could predispose to multiple BCC (MBCC). In this study, we therefore performed an exhaustive analysis of PTCH (mutations detection and deletion analysis) in 17 patients with the full complement of criteria for NBCCS (14 sporadic and three familial cases), and in 48 patients suspected of having a genetic predisposition to BCC (MBCC and/or age at diagnosis ⩽40 years and/or familial BCC). Eleven new germline alterations of the PTCH gene were characterised in 12 out of 17 patients harbouring the full complement of criteria for the syndrome (70%). These were frameshift mutations in five patients, nonsense mutations in five patients, a small inframe deletion in one patient, and a large germline deletion in another patient. Only one missense mutation (G774R) was found, and this was in a patient affected with MBCC, but without any other NBCCS criterion. We therefore suggest that patients harbouring the full complement of NBCCS criteria should as a priority be screened for PTCH mutations by sequencing, followed by a deletion analysis if no mutation is detected. In other clinical situations that suggest genetic predisposition to BCC, germline mutations of PTCH are not common.


Dermatology | 2010

Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

L. Boussemart; Simon Jacobelli; Frédéric Batteux; Claire Goulvestre; Philippe A. Grange; A. Carlotti; Jean-Pierre Morini; Isabelle Gorin; J.M. Ziza; M.-F. Avril; Nicolas Dupin

Background: Anti-tumor necrosis factor (TNF) agents are increasingly being used for a rapidly expanding number of rheumatic and systemic diseases. As a result of this use, and of the longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. The use of anti-TNF agents has been associated with more and more cases of autoimmune diseases, principally cutaneous vasculitis, lupus-like syndrome, systemic lupus erythematosus and interstitial lung disease. Observations: We report 2 cases of autoimmune bullous skin disease occurring in patients undergoing TNF-targeted therapy: a bullous pemphigoid and a pemphigus foliaceus. Both patients were treated by anti-TNF agents for rheumatoid arthritis and showed improvement following interruption of that treatment. Here, we discuss the relationship between anti-TNF therapy and the occurrence of autoimmune bullous disease. Conclusion: Anti-TNF agents should be considered as a potential cause of drug-induced autoimmune bullous skin disease.


Free Radical Biology and Medicine | 1997

OXIDATIVE MODULATION OF CYCLIC AMP-DEPENDENT PROTEIN KINASE IN HUMAN FIBROBLASTS : POSSIBLE ROLE IN PSORIASIS

Françoise Raynaud; Danièle Evain-Brion; Pascale Gerbaud; Denis Marciano; Isabelle Gorin; Charis Liapi; Wayne B. Anderson

Previous studies have established that cyclic AMP-dependent protein kinase (PKA) activity, as well as 8-azido-[32P]-cAMP binding to the RI and RII regulatory subunits, are decreased in cells from psoriatic patients compared to cells from normal patients. Here we show that the exposure of normal human dermal fibroblasts in culture to hydrogen peroxide and to oxygen free-radical generating systems decreased PKA activity, as well as cyclic AMP binding to the RI and RII regulatory subunits, to levels similar to those observed with psoriatic fibroblasts. Likewise, treatment of normal cytosolic preparations of PKA, as well as purified bovine PKA II, in vitro with free radical generating systems also resulted in decreased PKA activity and 8-azido [32P]-cAMP binding to the RI and RII regulatory subunits. Further, treatment of psoriatic fibroblasts with free radical scavenging agents such as vitamins E and C, and mannitol, and also with superoxide dismutase, restored the ability of RI and RII to bind 8-azido-[32P]-cAMP toward normal levels. Western blot analysis showed that the protein levels of the RI and RII subunits are similar in normal and psoriatic fibroblasts, and that the amounts of RI and RII are not altered by treatment of the cells with free radical-generating systems. These results suggest that oxidative modification may serve as a mechanism to alter PKA activity in human cells, and that an altered oxidative state may be involved in mediating the decrease in PKA activity and cyclic AMP binding noted in cells from psoriatic patients.


AIDS | 2008

Kaposi's sarcoma in HIV-negative men having sex with men.

Fanny Lanternier; Celeste Lebbe; Noël E.C. Schartz; David Farhi; Marcelin Ag; Delphine Kerob; Félix Agbalika; Olivier Vérola; Isabelle Gorin; M. Janier; Marie-Françoise Avril; Nicolas Dupin

Background:Four epidemiologic forms of Kaposis sarcoma have been described, all of which are associated with the human herpesvirus-8. In western countries, human herpesvirus-8 is more prevalent in homosexual men than in the general population, and anecdotal cases of Kaposis sarcoma in HIV-negative homosexual men have been reported. Patients and methods:We included HIV-negative homosexual and bisexual male patients with histologically proven Kaposis sarcoma in a retrospective study. Clinical data were collected using a standardized form. Risk factors for human herpesvirus-8 infection and for the development of Kaposis sarcoma were systematically recorded. Results:Between 1995 and 2007, 28 men met the defined inclusion criteria. Mean age at first symptoms of Kaposis sarcoma was 53 years. Clinical presentation resembled classical Kaposis sarcoma, with limited disease in most patients. No cellular or humoral immunodeficiency was observed. Serologic tests for human herpesvirus-8 (latent immunofluorescence assay) were positive in 88% of patients, and only two patients displayed human herpesvirus-8 viremia at the time of Kaposis sarcoma diagnosis. Three patients developed lymphoproliferative disorders (Castleman disease, follicular lymphoma and Burkitt lymphoma). In this population, α-interferon was well tolerated and gave a complete response, but most patients require only local treatment, if any. Conclusion:Kaposis sarcoma may develop in homosexual or bisexual men without HIV infection. This type of Kaposis sarcoma has clinical features in common with classical Kaposis sarcoma but occurs in younger patients. Its prognosis is good, as Kaposis sarcoma is generally limited, but clinicians should be aware of the association with lymphoproliferative diseases, which may affect prognosis.

Collaboration


Dive into the Isabelle Gorin's collaboration.

Top Co-Authors

Avatar

Nicolas Dupin

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Carlotti

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

N. Franck

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Marie Huraux

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge